Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes. Was simply stating boiler plate language that patent protection extends from filing date where previously started after issue date. Making the filling date more relevant.....assuming the patent issues.
The clock on patent expiration (20 years) starts from filling date. Previously (prior to 1995) it was 17 years from issue date. The issue date is less relevant than the filling date.
True. I was using drumbeat relative to the increased frequency not impact or recognition.
Agreed. Did not intend to imply they'd scale up site before it is ready. The equipment can be ready before the site in order to hit the ground running.
Not as much of a stretch as some would think it occurs in all sorts of manufacturing including pharmaceutical and perhaps now biologic. happens for various reasons too if it is happening in this instance it could be as simple as scaling up as some have speculated or it could be as exotic as Cognate being the keeper of the "secret sauce". If Cognate is placing capital equipment into Sawston perhaps a simple PR stating as much would ease some concerns especially in light of transfer ownership of NW shares from Cognate to the third party.
No arguments with getting the curtain lifted. NW is getting more pub recently today's motley article is another example. The previously non existent PR dept must have a hand in some of the persistent drum beat of late with more to come.
In Sawston I think you'll have NW employees working in a NW facility producing Direct on Cognate equipment.
Need to put some production capacity into Sawston to perform a trial on Direct. I'm guessing the third party investor (co)developed and/or produces the automated production system for Direct. With all the conjecture or moreover manipulation in regards to method B in phase I now with method B exclusively used in all phase II trials perhaps NW could provide further enlightenment into method B origins in phase II PR. Ready had some sage analysis a couple weekends ago and I completely agree a CI partnership brings further validation to Direct's data to date. The third trial covering the same ground as phase I is likely the one to be partnered and be done in other countries. Cueing off Ready's rather positive outlook on L I'll think NW may end up with two CI partners BMY in the States and Astra in UK. But only after phase I final analysis is complete.
A bit of a sticky wicket for some more than others.
Batch processing individualized vaccines how quaint.
You beat me to flight info.
What level of investment required to establish biologics production on two continents? For BMY it's nearly 2 billion dollars and their second facility won't be operational until 2019
Bristol-Myers Squibb to Build Biologics Plant in Ireland
Pharmaceutical Company Expects to Invest About $900 Million in New Facility
By
Michael Calia
Nov. 14, 2014 6:30 a.m. ET
0 COMMENTS
Bristol-Myers Squibb Co. on Friday said it plans to build a biologics plant in Cruiserath, Ireland, as the pharmaceutical company expands its global manufacturing presence.
Bristol-Myers said it expects the cost of the new plant to be comparable to the roughly $900 million it paid to build a biologics facility in Devens, Mass. The company said it expects to finalize the cost of the new plant during the second half of 2015.
Bristol-Myers said it expects about 350 to 400 scientists, engineers and other staffers to work at the Ireland site once construction is completed. The company projects the facility will be operational in 2019.
The move comes as biologic medicines are being used increasingly to treat major diseases, the company said, adding that the drugs make up more than half of its research-and-development pipeline.
Ireland has become a hot spot for the pharmaceutical industry, as U.S. companies have sought to expand in the country through so-called inversion deals that lower tax bills.
Write to Michael Calia at michael.calia@wsj.com
There is hope for brain cancers. Wish there was same hope for some of the pervasive thought cancers that persist.
Options expire on the 19th Friday. Don't ask me how I know you'll have to trust me on this.
In the interst of further disclosure It is a goal of mine to have at least one post deleted by the mods. It wil not be for the same rule resulting in fair amount of the recent deletions it will be most decidedly off topic. (This post if deleted does not count towards the goal)
As long as supposition is in play. What if NWBO has a proprietary manufacting process that makes never before seen attributes and maturation method B attainable?
Not too shabby of a endorsement with the addition to the Twitter following
Here is a thought to ponder as we wait for news. Suppose maturation method B was attained by NWBO's automated closed system for Direct production.
LP guilt by association their guy convicted. Is he a graduate of the Bernie Madoff investment school at Big House U?
Really liked the lint trap analogy.
Good read on the post and it’s about time I contributed something (of value) on this board…….IMO I wouldn’t worry about patents either as sometimes they help your competition figure out what you’re doing and how you’re doing it. I agree with the poster in a sense that it’s easy to make Dendritic vaccines as many entities have done so in the past…. and most have failed. Which as many here know is why NWBO routinely gets dismissed by AF and his ilk (even here on the board with our latest the Beloved Slappy) There are many very successful companies that have kept their formula secret (Coca-Cola) or sauce secret (Tabasco) without patents. I’m not saying Direct works but by all accounts there is some art to the science of making direct which would be hard if not impossible to replicate by competition. Especially if one considers how many have failed in the past. If Direct does work I would anticipate Cognate remaining a private enterprise with little “transparency” to NWBO shareholders. (I’ve never bought in to the argument that Cognate exists solely to enrich Linda et al. I do understand the argument and lets leave it at that)
Don’t have a lot of time now. I’ll try and expound on this a little further as time permits this week.
Thanks Senti.
Wow! "Let's play two!"
The perfect season remains intact.
A very eloquent reply Afford.
Interesting and thanks again. I wonder if the successful short play was invigorating enough to be the impetus to come back here and roll the dice before the expiration of self imposed posting embargo as the timing was right....Not to cast aspersions.
Hey TC, thanks for your posts great info. I'd like to pick your brain as well as point out a little more info on Pyrr. I totally agree with your assessment on stats and science. Albeit on analysis of ASCO presentation missed the color coding do the A & B regimen guess that is what happens when you have a narrative or agenda the data be damned. With the question I have I'll point you back to my post #35511 Duderaja had just pointed out to Afford that NBS recently surprised their shareholders with a secondary offering deflating the share price by approximately 30%. In an attempt to try and redirect the discussion I brought up the fact that someone (Pyrr) had recently suggested NBS as a much better investment than NWBO. At the time I thought I only had three free posts per day or I would have pursued redirection further.
In regards to my questions NBS would have made an excellent short if one had knowledge of secondary offering. My first question if you can answer is how long does it typically take to place a secondary offering? And I would imagine a fair amount of people at NBS and the brokerage house would have knowledge offering before it was made public correct?
Better have the juicers wired for 230v 50hz operation.....
Yes true at current burn rate.
Stay tuned.....
Tally-Ho! Some education in th UK today (see link from Jack)
I thought Slappy was trying to laugh off his own predicament. With several missed price collapse predictions the knickers must be getting a little tighter....
Wasn't NBS brought up by someone as a better investment than NWBO not too long ago?
If someone talks to Les the PR yesterday was well played. And do ask if color used in the ASCO presentation for the three B regimen survival bars is yellow, orange, or possibly grapefruit? (The latter most likely a corporate secret)
Large study in England and Woodford missed it....dude is slipping.
Yes. AF makes annual call to MD. MD switchboard puts him immediately through to Buzdar of course. With the ensuing exposay AF wins first Pulitzer.
With three and possibly more trials makes one wonder BP(s) brought their checkbook.....would make for nice PR Monday AM.
Nice dd. Do you also have an investment in IMUC speculative or otherwise?
Hindsightfull. With possible legal assistance to cover (not the short)....
All true. And please excuse me sticking with incitefull.
Yes, the article is incitefull....
Ok, Crazy.......Woodford not crazy.